[HTML][HTML] Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated …
TZ Horvat, NG Adel, TO Dang, P Momtaz… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
TZ Horvat, NG Adel, TO Dang, P Momtaz, MA Postow, MK Callahan, RD Carvajal…
Journal of Clinical Oncology, 2015•ncbi.nlm.nih.govPurpose Ipilimumab is a standard treatment for metastatic melanoma, but immune-related
adverse events (irAEs) are common and can be severe. We reviewed our large,
contemporary experience with ipilimumab treatment outside of clinical trials to determine the
frequency of use of systemic corticosteroid or anti-tumor necrosis factor α (anti-TNFα)
therapy and the effect of these therapies on overall survival (OS) and time to treatment
failure (TTF).
adverse events (irAEs) are common and can be severe. We reviewed our large,
contemporary experience with ipilimumab treatment outside of clinical trials to determine the
frequency of use of systemic corticosteroid or anti-tumor necrosis factor α (anti-TNFα)
therapy and the effect of these therapies on overall survival (OS) and time to treatment
failure (TTF).
Abstract
Purpose
Ipilimumab is a standard treatment for metastatic melanoma, but immune-related adverse events (irAEs) are common and can be severe. We reviewed our large, contemporary experience with ipilimumab treatment outside of clinical trials to determine the frequency of use of systemic corticosteroid or anti-tumor necrosis factor α (anti-TNFα) therapy and the effect of these therapies on overall survival (OS) and time to treatment failure (TTF).
ncbi.nlm.nih.gov